Evolving Role of Double and Triple Therapy With GLP 1 Receptor Agonists in Obesity and Cardiovascular Disease ScienceDirect In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Unveiling the Therapeutic Potential of the Second Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults Full article: Pharmacotherapy for Obesity: Recent Updates Tirzepatide vs. Semaglutide: Which GLP 1 Delivers Better Weight Loss? Pura Vida Med Spa